What you'll learn
- Evaluate molecularly targeted agents and immunotherapies approved or currently in clinical development for cancer treatment and incorporate into practice
- Assess relevant, state-of-the-art or translational pre-clinical models of anti-cancer therapies
- Recognize the steps and determinants of the metastatic process of cancer
- Identify the barrier for immunotherapy and potential approaches to address them
- Compare correlative studies of biomarkers and their response and resistance to targeted therapies in cancer patients
- Evaluate state-of-the-art genetic and imaging techniques and their applications in pre-clinical and clinical studies
This is an accredited, livestreamed course offered by Masssachusetts General Hospital. This course is targeted to physicians and researchers.
Select the Take Course button to view additional information on the course registration page.
Contact email@example.com with questions.
*Register before October 1 to receive the discounted price.
Harvard Medical School
You may also like
- Review the appropriate use and limitations of procalcitonin testing in the diagnosis and antibiotic management of infectious...
- Review the appropriate dosing and monitoring of NOACs and their appropriate use in different vulnerable patient populations.